Enicepatide Reduced Weight and A1c in Phase 2 Trial
A experimental once-weekly treatment met key efficacy goals in adults living with type 2 diabetes and obesity.
Updated on Sept. 28, 2026 in Diabetes
Live Poll
Do you trust emerging weight-loss and diabetes drugs as safe long-term health solutions?
A phase 2 clinical trial found that the synthetic peptide enicepatide led to significant weight loss and lowered hemoglobin A1c levels in adults with type 2 diabetes and obesity. The drug is currently under investigation and has not yet received regulatory approval.
Why it matters
As researchers seek new treatment options for the 600 million adults globally living with diabetes, this drug represents a new approach targeting multiple hormone receptors. If future trials confirm these findings, it could offer another therapeutic avenue for managing blood glucose and body weight.
In a phase 2 trial of 447 adults, participants receiving the highest dose of 24 mg of enicepatide saw a 2.65% reduction in hemoglobin A1c and 15.5% mean weight loss over 48 weeks. These results are preliminary, as the drug has not yet been approved by the FDA for any indication.
The players
Roche
A pharmaceutical company that develops diagnostic and therapeutic solutions for metabolic and chronic diseases.
The details
Enicepatide is a synthetic peptide that works by activating both GLP-1 and GIP receptors while favoring specific cAMP signaling pathways in the body. By engaging these receptors, the treatment is designed to influence glucose metabolism and satiety. In this trial, 2.0% of patients across all treatment arms discontinued the medication due to adverse events, which were primarily reported as mild-to-moderate gastrointestinal effects.
Timeline
The clinical trial treatment period lasted for 48 weeks.
Phase 3 glycemic control trials are planned for the first half of 2027.
Health Landscape
This development follows the established industry trend of testing multi-receptor agonist therapies to improve glycemic control and weight management outcomes. It contributes to the expanding body of research on dual-agonist peptides as the next potential evolution in metabolic health.
Because enicepatide is still in the trial phase, it is not available for clinical use or prescription. If you are managing type 2 diabetes or weight-related health concerns, it is worth discussing the current standard of care and newly approved treatment options with your physician.
The takeaway
While these early results for enicepatide are notable for their impact on A1c and weight, they remain preliminary. Patients should focus on proven, currently available treatments and continue to monitor their health markers through regular checkups with their healthcare provider.
What happens next
Roche intends to initiate phase 3 glycemic control programs and cardiovascular outcomes trials starting in the first half of 2027.
Further reading
For broader context on current approaches to blood sugar management, see our Diabetes section.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you trust emerging weight-loss and diabetes drugs as safe long-term health solutions?
